TY - JOUR
T1 - Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer
AU - Yamashita, Takuya
AU - Shiota, Masaki
AU - Machidori, Asako
AU - Kobayashi, Satoshi
AU - Matsumoto, Takashi
AU - Monji, Keisuke
AU - Kashiwagi, Eiji
AU - Takeuchi, Ario
AU - Takahashi, Ryosuke
AU - Inokuchi, Junichi
AU - Shiga, Ken ichiro
AU - Yokomizo, Akira
AU - Eto, Masatoshi
N1 - Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2021
Y1 - 2021
N2 - We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m2) between 2008 and 2018 were included. Among 125 Japanese men, 40 (32.0%) and 85 (68.0%) were treated with 3-weekly and 4-weekly regimens, respectively. In the 4-weekly regimen, the risks of progression, treatment failure, and any-cause mortality were comparable to those in the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. These data suggest that the 4-weekly regimen may be an acceptable option for selected patients.
AB - We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m2) between 2008 and 2018 were included. Among 125 Japanese men, 40 (32.0%) and 85 (68.0%) were treated with 3-weekly and 4-weekly regimens, respectively. In the 4-weekly regimen, the risks of progression, treatment failure, and any-cause mortality were comparable to those in the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. These data suggest that the 4-weekly regimen may be an acceptable option for selected patients.
UR - http://www.scopus.com/inward/record.url?scp=85099462102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099462102&partnerID=8YFLogxK
U2 - 10.1080/07357907.2020.1871486
DO - 10.1080/07357907.2020.1871486
M3 - Article
C2 - 33393849
AN - SCOPUS:85099462102
SN - 0735-7907
VL - 39
SP - 251
EP - 256
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -
